Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05181189 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NMDA Enhancement Combined With Omega-3 for Early Dementia

StatusNot Yet Recruiting
PhasePhase 2
Started2026-08
View on ClinicalTrials.gov ↗

Amendment history

2026-03-18
Study Status v4
Primary completion date2027-06→2028-03
Completion date2027-06→2028-03
Start date2024-07→2026-08
2024-02-06
Study Status v3
Primary completion date2026-07-31→2027-06
Completion date2026-07-31→2027-06
Start date2023-08-01→2024-07
2023-02-08
Study Status v2
Re-verified, no change to tracked fields
2022-10-13
Study Status v1
Start date2022-08-01→2023-08-01
2021-12-23
Original filing
In this 4-year proposed project, we will enroll 140 patients with aMCI or mild AD into a 24-week randomized, double-blind, placebo-controlled drug trial. All patients will be allocated randomly to one of two treatment groups for 24 weeks (n = 70 in each group) in a double-blind manner: \[1\] DAOIB + omega-3; \[2\] DAOIB + placebo. We will assess the patients every 8 weeks during the treatment period (weeks 0, 8, 16, and 24). We hypothesize that DAOIB combined with omega-3 will yield better efficacy than placebo in improving the cognitive function, global functioning and quality of life in patients with aMCI or mild AD.
Trial Details
NCT Number NCT05181189
Lead Sponsor Chang Gung Memorial Hospital
Conditions Omega 3 Fatty Acids, Dementia
Enrollment 140 participants
Start Date 2026-08
Primary Completion 2028-03 (estimated)
Study Completion 2028-03 (estimated)
Updated on ClinicalTrials.gov 2026-03-20